000147918 001__ 147918
000147918 005__ 20250923084433.0
000147918 0247_ $$2doi$$a10.3390/jcm13247627
000147918 0248_ $$2sideral$$a141411
000147918 037__ $$aART-2024-141411
000147918 041__ $$aeng
000147918 100__ $$aHerrero-Cortina, Beatriz
000147918 245__ $$aIncident cardiometabolic comorbidities in smokers with/without chronic obstructive pulmonary disease: a long-term cohort study
000147918 260__ $$c2024
000147918 5060_ $$aAccess copy available to the general public$$fUnrestricted
000147918 5203_ $$aDespite the significant global health impact of cardiometabolic multimorbidity (CMM), our understanding of potential predictors associated with its development in smokers, remains limited. Objective: This study aimed to investigate whether a new COPD diagnosis and the rate of lung function decline serve as predictors for incident CMM (defined as having at least two of the following comorbidities: cerebro-cardiovascular diseases, hypertension, dyslipidemia, and diabetes mellitus) in smokers. Methods: An observational longitudinal analysis of prospectively collected data was conducted, including smokers without a previous COPD diagnosis and any cardiometabolic conditions. Sociodemographic and clinical data (body mass index, smoking history, respiratory symptoms, and hospital admissions) were collected at baseline. Lung function tests were performed at baseline and at the end of the follow-up period. The incidence of CMM, a new positive diagnosis of COPD, and the forced expiratory volume in 1 s (FEV1) annual rate of decline were prospectively registered. Adjusted Cox proportional hazard models were adopted to explore risk factors associated with the incidence of CMM. Results: From the 391 smokers included in the study, 207 (53%) were newly diagnosed with COPD, and 184 had a preserved spirometry at baseline (non-COPD group). After nearly a decade of follow-up, 34% (n = 133) of smokers developed CMM. This group was characterized by male predominance, older age, higher BMI and pack-years of smoking, lower post-FEV1, baseline COPD diagnosis, and a history of hospital admission. A positive diagnosis of COPD at baseline and a greater rate of lung function decline (ΔFEV1 ≥ 40 mL/year) were independent predictors for developing CMM. Conclusions: A new COPD diagnosis and an accelerated decline in lung function are significantly associated with the development of CMM in smokers.
000147918 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000147918 590__ $$a2.9$$b2024
000147918 592__ $$a0.919$$b2024
000147918 591__ $$aMEDICINE, GENERAL & INTERNAL$$b65 / 332 = 0.196$$c2024$$dQ1$$eT1
000147918 593__ $$aMedicine (miscellaneous)$$c2024$$dQ1
000147918 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000147918 700__ $$aMaldonado-Guaje, Aura
000147918 700__ $$0(orcid)0000-0001-6351-0444$$aRodriguez-Sanz, Jorge$$uUniversidad de Zaragoza
000147918 700__ $$aBoldova-Loscertales, Ana$$uUniversidad de Zaragoza
000147918 700__ $$aCubero-Marin, Pablo
000147918 700__ $$aMarin-Oto, Marta$$uUniversidad de Zaragoza
000147918 700__ $$0(orcid)0000-0002-5228-248X$$aSanz-Rubio, David
000147918 700__ $$0(orcid)0000-0001-9096-2294$$aMarin, Jose M.$$uUniversidad de Zaragoza
000147918 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000147918 773__ $$g13, 24 (2024), 7627 [12 pp.]$$pJ. clin.med.$$tJournal of Clinical Medicine$$x2077-0383
000147918 8564_ $$s651770$$uhttps://zaguan.unizar.es/record/147918/files/texto_completo.pdf$$yVersión publicada
000147918 8564_ $$s2790887$$uhttps://zaguan.unizar.es/record/147918/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000147918 909CO $$ooai:zaguan.unizar.es:147918$$particulos$$pdriver
000147918 951__ $$a2025-09-22-14:44:40
000147918 980__ $$aARTICLE